Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Biosimilars

Research Grade Dilpacimab (HV571046)

Research Grade Dilpacimab
Research Grade Dilpacimab
Research Grade Dilpacimab
Research Grade Dilpacimab
Research Grade Dilpacimab
Research Grade Dilpacimab
Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview

  • Images

  • References

  • Datasheet

Overview
Catalog No.HV571046
Description
Dilpacimab (HV571046) is a research-grade recombinant antibody targeting Delta-like protein 4. Produced in mammalian cells with native-like glycosylation.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
  • Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivityHuman
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host speciesHumanized
IsotypeIgG1-kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4, Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession Q9NR61 & P15692
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate NamesBispecific, ABT-165, PR-1283233, 1791420-09-1
BackgroundDilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.
Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • Research Grade Dilpacimab

    SEC-HPLC

    SEC-HPLC detection for Research Grade Dilpacimab.

  • Research Grade Dilpacimab

    Bioactivity

    Detects VEGFA in indirect ELISAs.

  • Research Grade Dilpacimab

    SDS-PAGE

    SDS-PAGE for Research Grade Dilpacimab

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list